Molecular imaging: 18F-FDG PET and a whole lot more

Journal of Nuclear Medicine Technology

Volumn 37, Issue 3, 2009, Pages 151-161

  Peterson, Todd E ^a   Manning, H Charles ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

Instrumentation; Molecular imaging; Nonnuclear imaging methods; Oncology contrast agents

Indexed keywords

CONTRAST MEDIUM; COPPER 64; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; GALLIUM 68; GREEN FLUORESCENT PROTEIN; RADIOPHARMACEUTICAL AGENT; RECEPTOR; SUPERPARAMAGNETIC IRON OXIDE; TECHNETIUM 99M; TRACER; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; DIAGNOSTIC AGENT;

ANGIOGENESIS; APOPTOSIS; BIOLUMINESCENCE; CANCER DIAGNOSIS; CARBON NUCLEAR MAGNETIC RESONANCE; CELL FUNCTION; CELL PROLIFERATION; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG MANUFACTURE; DRUG RESEARCH; ECHOGRAPHY; FLUORESCENCE IMAGING; FLUORINE NUCLEAR MAGNETIC RESONANCE; HEALTH CARE COST; HUMAN; HYPERPOLARIZATION; HYPOXIA; MEDICAL RESEARCH; METABOLISM; MICROBUBBLE; MOLECULAR IMAGING; MOLECULAR PROBE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; PROTEIN TARGETING; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; GENETIC PROCEDURES; IMAGE ENHANCEMENT; METHODOLOGY;

FLUORODEOXYGLUCOSE F18; IMAGE ENHANCEMENT; MOLECULAR PROBE TECHNIQUES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 70249098815     PISSN: 00914916     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnmt.109.062729     Document Type: Review

References (78)

1. Mankoff DA. A definition of molecular imaging. J Nucl Med. 2007;48(6):18N, 21N.
2. Tolmachev V. Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des. 2008;14:2999-3019.
3. 18F- fluoroestradiol. J Nucl Med. 2008;49:367-374.
4. Dehdashti F, Mortimer JE, Trinkaus K, et al. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer. Breast Cancer Res Treat. 2009;113:509-517.
5. Preul MC, Caramanos Z, Collins DL, et al. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med. 1996;2:323-325. (Pubitemid 26080653)
6. 13C-1-pyruvate. Magn Reson Med. 2007;58:65-69.
7. Wilson SR, Burns PN. Microbubble contrast for radiological imaging: 2. Applications. Ultrasound Q. 2006;22:15-18.
8. Lindner JR. Molecular imaging with contrast ultrasound and targeted microbubbles. J Nucl Cardiol. 2004;11:215-221. (Pubitemid 38949915)
9. Park SY, Wang X, Chen Z, et al. Optical imaging of pancreatic beta cells in living mice expressing a mouse insulin I promoter-firefly luciferase transgene. Genesis. 2005;43:80-86. (Pubitemid 41598817)
10. Hsiung PL, Hardy J, Friedland S, et al. Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nat Med. 2008;14:454-458.
11. Sampath L, Kwon S, Ke S, et al. Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer. J Nucl Med. 2007;48:1501-1510. (Pubitemid 47397400)
12. Wester HJ. Nuclear imaging probes: from bench to bedside. Clin Cancer Res. 2007;13:3470-3481. (Pubitemid 46955106)
13. 18F-fluoroethyl)-L- tyrosine PET and proton magnetic resonance spectroscopic imaging. J Nucl Med. 2008;49:721-729.
14. Reinhardt MJ, Kubota K, Yamada S, Iwata R, Yaegashi H. Assessment of cancer recurrence in residual tumors after fractionated radiotherapy: a comparison of fluorodeoxyglucose, L-methionine and thymidine. J Nucl Med. 1997;38:280-287. (Pubitemid 27061613)
15. Shields AF, Mankoff D, Graham MM, et al. Analysis of 2-carbon-11- thymidine blood metabolites in PET imaging. J Nucl Med. 1996;37:290-296. (Pubitemid 26150906)
16. Shields AF, Mankoff DA, Link JM, et al. Carbon-11-thymidine and FDG to measure therapy response. J Nucl Med. 1998;39:1757-1762. (Pubitemid 28473526)
17. 18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging. 2004;31:1659-1672.
18. 18F-FDG. J Nucl Med. 2005;46:945-952.
19. Choi SJ, Kim JS, Kim JH, et al. [F-18]3′-deoxy-3′- fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging. 2005;32:653-659. (Pubitemid 40897487)
20. Cobben DCP, Elsinga PH, van Waarde A, Jager PL. Correspondence re: H. Barthel et al., 3′-deoxy-3′-[F-18]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003;63:3791-3798.
21. 18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging. 2003;30:1407-1412.
22. Grierson JR, Schwartz JL, Muzi M, Jordan R, Krohn KA. Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. Nucl Med Biol. 2004;31:829-837. (Pubitemid 39297680)
23. 18F]FLT in high activities [abstract]. J Nucl Med. 2001;42(suppl):257P.
24. Plagemann PG, Wohlhueter RM, Woffendin C. Nucleoside and nucleobase transport in animal cells. Biochim Biophys Acta. 1988;947:405-443. (Pubitemid 18239989)
25. 3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol. 2002;29:281-287.
26. Arner ES, Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol Ther. 1995;67:155-186.
27. Wagner M, Seitz U, Buck A, et al. 39-[F-18]fluoro-39-deoxythymidine ([F-18]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res. 2003;63:2681-2687. (Pubitemid 36605213)
28. 18F-fluorothymidine PET. J Nucl Med. 2005;46:114-120.
29. Choi SJ, Kim JS, Kim JH, et al. [18F]3′-deoxy-3′- fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging. 2005;32:653-659. (Pubitemid 40897487)
30. 18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 2004;10:2245-2252.
31. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med. 1999;40:177-183.
32. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26:239-257.
33. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem. 1999;68:383-424.
34. Blankenberg FG. Molecular imaging: the latest generation of contrast agents and tissue characterization techniques. J Cell Biochem. 2003;90:443-453.
35. Haas RL, de Jong D, Valdes Olmos RA, et al. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int J Radiat Oncol Biol Phys. 2004;59:782-787.
36. 99mTc-annexin V scintigraphy: visual analysis in relation to treatment response. Radiother Oncol. 2004;72:333-339.
37. 99mTc-HYNIC annexin-V imaging in squamous cell carcinoma of the head and neck. Eur J Nucl Med Mol Imaging. 2008;35:47-52.
38. Rottey S, Loose D, Vakaet L, et al. 99mTc-HYNIC annexin-V imaging of tumors and its relationship to response to radiotherapy and/or chemotherapy. Q J Nucl Med Mol Imaging. 2007;51:182-188. (Pubitemid 47064658)
39. 99mTc-HYNIC annexin-V imaging in head and neck carcinoma. Cancer Biother Radiopharm. 2004;19:205-210.
40. Kietselaer BL, Reutelingsperger CP, Heidendal GA, et al. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med. 2004;350:1472-1473.
41. Thimister PW, Hofstra L, Liem IH, et al. In vivo detection of cell death in the area at risk in acute myocardial infarction. J Nucl Med. 2003;44:391-396.
42. Rongen GA, Oyen WJ, Ramakers BP, et al. Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation. 2005;111:173-178.
43. Kietselaer BL, Reutelingsperger CP, Heidendal GA, et al. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. New Engl J Med. 2004;350:1472-1473.
44. 99mTc-HYNIC-annexin V SPECT imaging of acute stroke and its response to neuroprotective therapy with anti-Fas ligand antibody. Eur J Nucl Med Mol Imaging. 2006;33:566-574.
45. Lorberboym M, Blankenberg FG, Sadeh M, Lampl Y. In vivo imaging of apoptosis in patients with acute stroke: correlation with blood-brain barrier permeability. Brain Res. 2006;1103:13-19.
46. Lampl Y, Lorberboym M, Blankenberg FG, Sadeh M, Gilad R. Annexin V SPECT imaging of phosphatidylserine expression in patients with dementia. Neurology. 2006;66:1253-1254. (Pubitemid 43739715)
47. Ohnishi S, Vanderheyden JL, Tanaka E, et al. Intraoperative detection of cell injury and cell death with an 800 nm near-infrared fluorescent annexin V derivative. Am J Transplant. 2006;6:2321-2331. (Pubitemid 44359417)
48. Schellenberger EA, Weissleder R, Josephson L. Optimal modification of annexin V with fluorescent dyes. Chembiochem. 2004;5:271-274. (Pubitemid 39257119)
49. Manning HC, Merchant NB, Foutch AC, et al. Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res. 2008;14:7413-7422.
50. Volkow ND, Wang GJ, Telang F, et al. Dopamine increases in striatum do not elicit craving in cocaine abusers unless they are coupled with cocaine cues. NeuroImage. 2008;39:1266-1273.
51. Mukherjee J, Christian BT, Dunigan KA, et al. Brain imaging of 18F-fallypride in normal volunteers: blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse. 2002;46:170-188. (Pubitemid 35155170)
52. 11C-raclopride in living human brain: a search for extrastriatal central D2-dopamine receptors by PET. Psychopharmacology (Berl). 1988;94:471-478.
53. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24:2793-2799.
54. 64Cu-DOTA-cetuximab in 5 cervical cancer cell lines. J Nucl Med. 2008;49:1472-1479.
55. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
56. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989;339:58-61. (Pubitemid 19115892)
57. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851-858. (Pubitemid 19162712)
58. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971;133:275-288.
59. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306-1309. (Pubitemid 20066716)
60. Vaisman N, Gospodarowicz D, Neufeld G. Characterization of the receptors for vascular endothelial growth factor. J Biol Chem. 1990;265:19461-19466. (Pubitemid 120013886)
61. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003;17:545-580.
62. 99mTc-HYNIC-VEGF. Eur J Nucl Med Mol Imaging. 2006;33:841-848.
63. Blankenberg FG, Mandl S, Cao YA, et al. Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor. J Nucl Med. 2004;45:1373-1380. (Pubitemid 47618538)
64. Cai W, Chen K, Mohamedali KA, et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med. 2006;47:2048-2056. (Pubitemid 47544993)
65. 111In for imaging tumor angiogenesis. J Nucl Med. 2005;46:1745-1752.
66. 124I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography. Cancer Res. 2002;62:5912-5919.
67. 123I]-VEGF165 as a potential tumor marker. Nucl Med Biol. 2005;32:431-436.
68. 123I-VEGF165): biodistribution, safety and radiation dosimetry in patients with pancreatic carcinoma. Q J Nucl Med Mol Imaging. 2004;48:198-206.
69. Lu E, Wagner WR, Schellenberger U, et al. Targeted in vivo labeling of receptors for vascular endothelial growth factor: approach to identification of ischemic tissue. Circulation. 2003;108:97-103. (Pubitemid 36859027)
70. Yoshimoto M, Kinuya S, Kawashima A, Nishii R, Yokoyama K, Kawai K. Radioiodinated VEGF to image tumor angiogenesis in a LS180 tumor xenograft model. Nucl Med Biol. 2006;33:963-969. (Pubitemid 44791953)
71. Backer MV, Levashova Z, Patel V, et al. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med. 2007;13:504-509. (Pubitemid 46559824)
72. Virostko J, Xie J, Hallahan DE, Arteaga CL, Gore JC, Manning HC. A molecular imaging paradigm to rapidly profile response to angiogenesis-directed therapy in small animals. Mol Imaging Biol. 2009;11:204-212.
73. McIntyre JO, Fingleton B, Wells KS, et al. Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity. Biochem J. 2004;377:617-628. (Pubitemid 38228373)
74. McIntyre JO, Matrisian LM. Molecular imaging of proteolytic activity in cancer. J Cell Biochem. 2003;90:1087-1097. (Pubitemid 37485047)
75. Louie AY, Huber MM, Ahrens ET, et al. In vivo visualization of gene expression using magnetic resonance imaging. Nat Biotech. 2000;18:321-325.
76. Moats RA, Fraser SE, Meade TJ. A "'smart" magnetic resonance imaging agent that reports on specific enzymatic activity. Angew Chem-Int Ed Eng. 1997;36:726-728.
77. Nivorozhkin AL, Kolodziej AF, Caravan P, Greenfield MT, Lauffer RB, McMurry TJ. Enzyme-activated Gd(31) magnetic resonance imaging contrast agents with a prominent receptor-induced magnetization enhancement. Angew Chem Int Ed Engl. 2001;40:2903-2906.
78. Shah C, Miller TW, Wyatt SK, et al. Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res. 2009;15:4712-4721.